HC Wainwright Issues Optimistic Estimate for ASND Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Analysts at HC Wainwright raised their FY2026 EPS estimates for Ascendis Pharma A/S in a research report issued to clients and investors on Monday, August 31st. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will post earnings of $17.04 per share for the year, up from their previous forecast of $3.93. HC Wainwright currently has a “Buy” rating and a $345.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is $3.90 per share.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The company had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million.

Several other research firms also recently commented on ASND. Royal Bank Of Canada upped their target price on Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a research report on Friday, August 14th. Citigroup assumed coverage on Ascendis Pharma A/S in a research note on Monday, May 18th. They issued a “buy” rating and a $355.00 price target for the company. Bank of America decreased their price objective on Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a report on Monday. BMO Capital Markets started coverage on Ascendis Pharma A/S in a research report on Tuesday, August 18th. They set an “outperform” rating and a $319.00 price objective on the stock. Finally, Oppenheimer reissued an “outperform” rating and issued a $312.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $310.05.

Ascendis Pharma A/S Trading Down 1.1%

Shares of ASND stock opened at $260.25 on Wednesday. The firm has a 50 day moving average price of $256.87 and a two-hundred day moving average price of $239.75. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $16.23 billion, a PE ratio of 20.19 and a beta of 0.35. Ascendis Pharma A/S has a 12-month low of $186.05 and a 12-month high of $282.15.

Institutional Trading of Ascendis Pharma A/S

Several large investors have recently modified their holdings of the stock. Nomura Asset Management Co. Ltd. boosted its holdings in shares of Ascendis Pharma A/S by 57.5% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 43,701 shares of the biotechnology company’s stock valued at $9,319,000 after acquiring an additional 15,950 shares in the last quarter. Candriam S.C.A. grew its stake in shares of Ascendis Pharma A/S by 23.2% in the 1st quarter. Candriam S.C.A. now owns 230,278 shares of the biotechnology company’s stock valued at $52,671,000 after buying an additional 43,338 shares during the period. Orbimed Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 5.8% during the first quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company’s stock valued at $41,624,000 after acquiring an additional 10,000 shares in the last quarter. Perceptive Advisors LLC grew its position in Ascendis Pharma A/S by 41.6% in the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after purchasing an additional 450,000 shares during the period. Finally, Eagle Health Investments LP acquired a new position in shares of Ascendis Pharma A/S during the first quarter valued at about $19,819,000.

Insider Activity

In related news, Director Jean Jacques Bienaime purchased 2,000 shares of Ascendis Pharma A/S stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average price of $246.33 per share, with a total value of $492,660.00. Following the completion of the transaction, the director directly owned 2,900 shares of the company’s stock, valued at $714,357. This represents a 222.22% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 40.00% of the company’s stock.

Key Ascendis Pharma A/S News

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Ascendis Pharma and BioMarin entered a binding term sheet for a global settlement and license agreement related to YUVIWEL (navepegritide). The agreement appears to reduce legal and commercial uncertainty surrounding the program and initially drove a strong move in the shares. Ascendis Pharma and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL
• Positive Sentiment: HC Wainwright dramatically raised its FY2026 EPS forecast to $17.04 from $3.93 while maintaining a Buy rating and a $345 price target. The new estimate is well above the broader full-year consensus of $3.90, signaling substantial expected earnings growth.
• Positive Sentiment: Wedbush reaffirmed its Outperform rating and $327 price target, implying substantial upside from the reference price of $260.25. Wedbush Reaffirms Ascendis Pharma Rating
• Neutral Sentiment: Ascendis Pharma received an average analyst rating of Buy, indicating that Wall Street sentiment remains favorable despite recent estimate changes. Ascendis Pharma Receives Average Rating of Buy from Analysts
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for Q3 and Q4 2026 and every quarter listed for 2027. Its FY2027 estimate fell to $11.25 from $11.88, suggesting a slower near-term earnings ramp even though the firm retained its Buy rating and $345 target.
• Negative Sentiment: Bank of America reduced its price target to $304 from $306 while maintaining a Buy rating. The small cut is not a change in overall recommendation, but it may reinforce concerns about valuation or near-term execution. Bank of America Lowers Ascendis Pharma Price Target

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.